Microbiota Restoration Therapy Presentations

RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection, Is Safe and Effective: Results from a Randomised, Double-Blinded, Placebo-Controlled Trial

Robert Orenstein, DO, Mayo Clinic in Arizona, Phoenix, AZ

Perspectives on the PUNCH CD Trial of a Microbiota-Based Drug Targeted at Recurrent C. diff. Infection

Kathy Tracey, LPN, CCRC, Manager of Clinical Research, Chevy Chase Clinical Research, Chevy Chase, MD; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc., Roseville, MN

Results of the Phase 2 PUNCH™ CD Safety Study of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection

Erik Dubberke, MD, MSPH, Washington University School of Medicine, St. Louis, MO; Robert Orenstein, DO, Mayo Clinic Arizona, Phoenix, AZ; Kathleen Mullane, DO, PharmD, University of Chicago Medicine, Chicago, IL; Robert Hardi, MD, Capital Digestive Care, Chevy Chase, MD; Arnab Ray, MD, Ochsner Clinic, New Orleans, LA; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc., Roseville, […]

Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antibiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study

Paul G Mariani, MD, Sanford Health, Fargo, ND; Connie S. Price, MD, Denver Health, Denver, CO; Robert Orenstein, DO, Mayo Clinic, Phoenix, AZ; Hill Harris, MD, MPH, Denver Health, Denver, CO; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc, Roseville, MN Background Fecal transplant is a promising non-antibiotic treatment option for refractory/recurrent Clostridium difficile infection and […]